MedTrace Logo

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

NCT02172157 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2014-06-24

No results posted yet for this study

Summary

Primary objective:

To determine the basic pharmacokinetics of BI 1744 BS, its metabolite BI 1744 BS - glucuronide and \[14C\]-radioactivity including excretion mass balance, excretion pathways and metabolism following intravenous and oral administration of \[14C\]BI 1744 CL

Secondary objective:

To determine safety and tolerability following intravenous and oral administration of \[14C\]BI 1744 CL in healthy male subjects

Conditions

  • Healthy

Interventions

DRUG

BI 1744 CL i.v.

DRUG

BI 1744 CL oral

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172157 on ClinicalTrials.gov